Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib in Refractory Indolent B-Cell Non-Hodgkin Lymphoma
NCT01282424Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2011
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of idelalisib in follicular lymphoma (FL), small lymphocytic lymphoma (SLL), Lymphoplasmacytic Lymphoma (LPL), marginal zone lymphoma (MZL), sponsored by Gilead Sciences. Started Mar 2011; status: completed.
02
Drugs
idelalisib
03
Conditions
follicular lymphoma (FL)small lymphocytic lymphoma (SLL)Lymphoplasmacytic Lymphoma (LPL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT01282424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01282424.